Soldevilla MM, Villanueva H, Meraviglia-Crivelli D, Menon AP, Ruiz M, Cebollero J, Villalba M, Moreno B, Lozano T, Llopiz D, Pejenaute A, Sarobe P, Pastor F. ICOS costimulation at the tumor site in combination with CTLA-4 blockade therapy elicits strong tumor immunity. Mol Ther. 2019 Nov 6;27(11):1878-91. doi: 10.1016/j.ymthe.2019.07.013
Shi K, Zhao Y, Miao L, Satterlee A, Haynes M, Luo C, Musetti S, Huang L. Dual functional LipoMET mediates envelope-type nanoparticles to combinational oncogene silencing and tumor growth inhibition. Mol Ther. 2017 Jul 5;25(7):1567-79. doi: 10.1016/j.ymthe.2017.02.008
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.